Momelotinib provides significant improvements in patients with myelofibrosis

Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international Phase III MOMENTUM trial led by researchers at University of Texas MD Anderson Cancer Center.

The findings, published in prestigious medical journal The Lancet, support the use of momelotinib – a potent ACVR1/ALK2 and JAK1/2 inhibitor – over the standard therapy danazol in treating myelofibrosis patients that were resistant, refractory or intolerant to firstline therapy, especially symptomatic patients and those with anemia.

“Current options for managing anemia in our myelofibrosis patients provide only modest and temporary benefits, so we are excited about these findings,” said study lead Dr Srdan Verstovser, professor of Leukemia, adding: “The trial results suggest that momelotinib is safe, well-tolerated and can improve one of the most common and debilitating clinical problems for this patient population.”